Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

and development expenses for the year ended December 31, 2008 totaled $46.5 million compared with $38.9 million in 2007. Research and development expenses were $13.9 million for the three months ended December 31, 2008 compared to $9.3 million for the same quarter the previous year. The increase in expenses was the net result of: achieving full enrolment of clinical sites and patients in the MAESTRO-03 trial; increased costs for the MAESTRO-02 trial as patients enter the trial; reduced costs of the MAESTRO-01 and MINDSET-01 trials as more patients complete these trials; a decrease in drug manufacturing expenses as the manufacture of validation batches is completed; a licensing bonus payment related to the Agreement with Lilly, and; additional expenses related to alliance management and support.

At December 31, 2008, cash and cash equivalents and short-term investments totaled $90.4 million as compared to $37.9 million at December 31, 2007. At December 31, 2008, the Company had working capital of $81.3 million as compared to $32.8 million at December 31, 2007. Management estimates that the current working capital is sufficient for the Company to meet its obligations in respect of the currently initiated clinical trials.

As at December 31, 2008 there were 91,009,323 Class "A" common shares of the Company issued and outstanding.

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchan
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... NY (PRWEB) , ... July 03, 2015 , ... Cuvettes have been used in countless ... style catalog to find the cuvette they needed. As expected, this was a daunting ... order the wrong part because they were not able to navigate the complex catalog structure. ...
(Date:7/2/2015)... ... 02, 2015 , ... In’Tech Medical SAS ( http://www.intech-medical.com ), ... today the acquisition of Turner Medical, Inc ., thus becoming a global ... the Spine Industry. The acquisition of Turner Medical ideally supplements In’Tech Medical’s product ...
(Date:7/1/2015)... AURORA, Colo. and BANGALORE, India ... a global genomic profiling company that uses next generation ... appointment of Scott A. Storrer as chief ... and CEO, he will be responsible for all strategy, ... Vijay Chandru , who has served as Strand,s chairman ...
(Date:7/1/2015)... InferMed , s ... will augment Elsevier ... olutions suite   Elsevier , a world-leading ... announced today the acquisition of  InferMed , a ... InferMed,s Arezzo technology supports clinicians in choosing the most ...
Breaking Biology Technology:New Cuvette E-Commerce Website Launched by FireflySci 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4
... PRINCETON, N.J., April 30 Medarex, Inc. (Nasdaq: ... ended March 31, 2009. Medarex,s net loss for the quarter ... share. For the same period in 2008, Medarex,s net income ... of $151.8 million, or $1.19 per share, from the sale ...
... AUSTIN, TexasWith two $15 million grants, scientists and engineers ... science for geological storage of greenhouse gases as part ... The University of Texas at Austin by the U.S. ... the creation of 46 new EFRCs nationally in conjunction ...
... Qutenza(TM) (NGX-4010)Identification of Impact of PHN and PDN ... /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: ... developing and commercializing novel pain management therapies, announced ... 61st Annual American Academy of Neurology (AAN) meeting ...
Cached Biology Technology:Medarex Announces 2009 First Quarter Financial Results 2Medarex Announces 2009 First Quarter Financial Results 3Medarex Announces 2009 First Quarter Financial Results 4Medarex Announces 2009 First Quarter Financial Results 5Medarex Announces 2009 First Quarter Financial Results 6Medarex Announces 2009 First Quarter Financial Results 7Medarex Announces 2009 First Quarter Financial Results 8Medarex Announces 2009 First Quarter Financial Results 9Solar cells, geological storage research receive DOE funding at the University of Texas at Austin 2Solar cells, geological storage research receive DOE funding at the University of Texas at Austin 3NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting 2NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting 3NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting 4NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting 5
(Date:6/24/2015)... YORK , June 24, 2015 The ... rate. The major drivers for the market include growth ... number of new drug launches. Over the years, the ... increased. Between 2001 and 2010, the FDA approved 225 ... according to WIPO, Europe accounted ...
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
(Date:6/23/2015)... Fla. , June 23, 2015 /PRNewswire/ ... management and authentication solutions, today announced enhanced functionality ... multi-factor authentication solution.  The enhancements build on ... of the DigitalPersona Altus platform and provide ... compatibility. In today,s environment of ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
... protein known as PEPT2 protects the brains of mice ... present in lead poisoning and in a class of ... Scientists at the University of Michigan found ... (5-ALA), mice without the PEPT2 protein died sooner, had ...
... PARK, MD -- Many fruit farmers in the ... to realize profits and create repeat business. Pick-your-own ... consumer satisfaction with the experience is critical to ... team of researchers from the University of Maryland, ...
... bacteria discovered living in one of the most extreme environments ... global warming. , In a paper published today in the ... Dunfield and colleagues describe the methane-eating microorganism they found in ... of Rotorua in New Zealand. It is the hardiest methanotrophic ...
Cached Biology News:Strawberry fields ripe for the picking 2'Hellish' hot springs yield greenhouse gas-eating bug 2
Mouse monoclonal [RIZ1723] to PRDM2/RIZ...
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
... GenBank Accession Number : NM_002542 Immunogen ... corresponding to residues 166-223 of human AP-2α ... 0.1M Tris-glycine, pH 7.4, 0.15M NaCl, 0.05% ... to 30% Quality Assurance: routinely evaluated by ...
Biology Products: